Our research and trials staff are dedicated and experienced professionals, interested in pushing the boundaries of our knowledge and testing new ideas in practical environments. Use the links below to jump to categorised trials.

Myeloma X
Type: NCRI, multi-centre, phase III, randomised study
Eligibility: Relapsed myeloma (1st disease progression following previous autograft) needing treatment in patients > 18 years of age who are suitable for high dose therapy NB: patients with progressive disease needing treatment within 18 months of previous autograft are excluded. Patients with severe neuropathy or significant renal impairment (GFR of <30 ml/min) are also excluded.
Study details: Assesses the role of a 2nd autograft as consolidation therapy in myeloma patients relapsing at least 18 months after a previous autograft. All patients will receive between 2-4 cycles of PAD chemotherapy to re-induce remission. Responding patients will then be randomised to consolidation with either high dose therapy (2nd autograft) or with weekly cyclophosphamide for 12 weeks.
Myeloma XI
Type: A randomised comparison of thalidomide and lenalidomide combinations in myeloma patients of all age groups
Eligibility: Age 18 years or greater Newly diagnosed as having symptomatic multiple myeloma or non-secretory multiple myeloma. Paraprotien (M-protein) in serum and/or urine. Bone marrow clonal plasma cells or plasmacytoma Related organ or tissue impairment and/or symptoms considered by the clinician to be myeloma related
Study details: For younger/fitter patients where intensive HDT with stem cell support is considered appropriate. For older/less patients where standard-dose chemotherapy is considered appropriate.
Type: Multicentre, Phase II study
Eligibility: Previously untreated patients with symptomatic myeloma. Patients suitable for high dose therapy and ASCT. Age 18 or older. Performance score (PS) of 0-3 (ECOG).
Study details: Phase II study of Bortezomib, Adriamycin and Dexamethasone (PAD) therapy of previously untreated patients with multuple myeloma; Impact of minimal residual disease (MRD) in patients with deffered ASCT (PADIMAC).
TEAMM (pending)
Type: Multicentre, randomised, double-blind, placebo-controlled trial
Eligibility: Age 21 or older and able to give informed consent. Patient with newly diagnosed symptomatic myeloma based on internationally agreed critieria. Patient that is no more than 7 days to starting a programme of anti-myeloma therapy or within 14 days into starting anti-myeloma therapy if already on a broad spectrum antibacterial agent.
Study details: Tackling early morbidity and motality in Myeloma: Assessing the benefit of antibiotic prophylaxis and its effect on healthcare associated infections.